Table of Contents
1
UI - 11889695
AU - Leenman EE; Tsinzerling VA; Pozharisskii KM
TI -
[Morphological and immunohistochemical characteristics of primary brain
lymphomas in AIDS patients]
SO - Arkh Patol 2002 Jan-Feb;64(1):25-9
AD - N.N. Petrov Cancer Research Institute, 186646, St-Petersburg.
Primary lymphomas of the brain were studied in 6 AIDS patients. The
lymphomas were characterized by multicentricity, extended necroses and
location in large hemispheres. Two types of tumor cell growth were
recorded: diffuse and perivascular with vascular wall destruction.
According to the International Histologic Classification (2001), these
lymphomas were classified as diffuse B-cell large cell lymphomas
subdivided into 3 variants: immunoblastic with plasma cell
differentiation, centroblastic polymorphic and large cell anaplastic (by
Kils classification criteria). Immunohistochemically (LMP-1) and by
hybridization in situ (RNA EBER-1,2) Epstein-Barr virus was found in
tumor cells from all the patients. In 5 of 6 cases studied expression of
the antiapoptotic protein bcl-2 and in 2 cases expression of mutant p53
were revealed.
2
UI - 11884058
AU - Bhama JK; Azad NS; Fisher WE
TI -
Primary anorectal lymphoma presenting as a perianal abscess in an
HIV-positive male.
SO - Eur J Surg Oncol 2002 Mar;28(2):195-7
AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine and
The Veteran Affairs Medical Center, Houston, Texas 77030, USA.
3
UI - 11699213
AU - Preciado MV; De Matteo E; Fallo A; Chabay P; Drelichman G; Grinstein S
TI -
EBV-associated Hodgkin's disease in an HIV-infected child presenting
with a hemophagocytic syndrome.
SO - Leuk Lymphoma 2001 Jun;42(1-2):231-4
AD - Laboratory of Virology, Ricardo Gutierrez Children Hospital, Gallo 1330,
1425 Ciudad de Buenos Aires, Argentina. preciado@conicet.gov.ar
An 8-years-old boy was admitted with fever of unknown origin, cervical
lymphadenopathy and hepatosplenomegaly and weight loss. His mother's HIV
infection was diagnosed two weeks before his hospitalization, so he was
diagnosed as perinatally acquired AIDS. Serology and serial cultures
were negative for viral infections, toxoplasmosis, chagas, tuberculosis
and atypical mycobacterium. The patient met clinical and laboratory
criteria for hemophagocytic syndrome (HS) that was confirmed on bone
marrow aspirate and biopsy. A cervical lymph node biopsy was performed
which was diagnosed as Hodgkin's disease (HD) diffuse fibrosis
lymphocyte depletion subtype. EBERs in situ hybridization and LMP-1
immunohistochemistry on the lymph node biopsy established the EBV
association. On the basis of a sequence of appearance of the clinical,
laboratory and histological signs, HIV, EBV or HD may have triggered HS
as the last fatal event in this pediatric patient.
4
UI - 11860669
AU - Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
TI -
AIDS-related systemic non-Hodgkin's lymphoma at a large community
program.
SO - AIDS Res Hum Retroviruses 2002 Mar 1;18(4):237-42
AD - Department of Medicine, Baylor Center for AIDS Research, Baylor College
of Medicine, Houston, Texas 77030, USA. rvilchez@bcm.tmc.edu
The introduction of triple antiretroviral therapy has led to reductions
in opportunistic diseases in HIV-infected patients. However, little is
known of the effect of this therapy on the clinical and pathological
features and the outcome of patients with AIDS-related systemic
non-Hodgkin's lymphoma (NHL). We examined the incidence and clinical
manifestations of HIV-infected patients with systemic NHL at the Harris
County Hospital District and Veterans Affairs Medical Center (Houston,
were diagnosed in 3655 HIV-infected patients. Three groups of patients
diagnosed with systemic NHL were identified according to their history
of antiretroviral therapy: treatment naive (n = 20), dual nucleoside (n
= 22), and triple antiretroviral drug-treated patients (n = 34). The
median duration of antiretroviral therapy before the diagnosis of
systemic NHL in the triple antiretroviral and dual nucleoside treatment
groups was 12 versus 8 months (p < 0.0004). Thirty-five percent of
patients (12 of 34) in the triple treatment group had an HIV RNA viral
load of <400 copies/ml and their median CD4+ cell count was 301
cells/mm(3) (range, 46 to 667 cells/mm(3)) at the time of diagnosis of
systemic NHL. More patients treated with triple antiretroviral therapy
received complete courses of chemotherapy as compared with the other two
groups (p = 0.013). However, the overall survival did not differ
significantly among the three groups of patients. These data suggest
that AIDS-related systemic NHL continues to occur even in patients
treated with triple antiretroviral therapy. In addition, this
opportunistic malignancy is associated with significant mortality.
Therefore, it is necessary to develop a better understanding of the
pathogenesis of this disease.
5
UI - 11872995
AU - Powles T; Imami N; Nelson M; Gazzard BG; Bower M
TI -
Effects of combination chemotherapy and highly active antiretroviral
therapy on immune parameters in HIV-1 associated lymphoma.
SO - AIDS 2002 Mar 8;16(4):531-6
AD - Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham
Road, London SW10 9NH, UK.
OBJECTIVE: To measure the effects of combined chemotherapy and highly
active antiretroviral therapy (HAART) on immune cell counts and plasma
HIV-1 RNA loads in patients with AIDS-related lymphoma (ARL) to
determine the implications for opportunistic infection prophylaxis and
medium-term immune function. DESIGN AND METHODS: Peripheral blood total
lymphocyte count, CD4 T-cell count, CD8 T-cell count, CD19 B-cell count,
CD16/CD56 natural killer cell count and plasma HIV-1 RNA load were
prospectively measured at ARL diagnosis, at 1 and 3 months during and 1,
3 and 6 months after chemotherapy in twenty patients receiving HAART.
RESULTS: Significant declines in T-helper cell (CD4) count, natural
killer cell (CD16/CD56) and B lymphocyte count (CD19 cells) occurred
during the first 3 months of chemotherapy. There was no significant
alteration in the T-cytotoxic cell (CD8) count, CD4 percentage or HIV-1
RNA load during the study period. The T-helper cell and natural killer
cell counts recovered to pre-treatment levels within 1 month of
finishing chemotherapy. The recovery of B-cells was slower with
pre-treatment levels only being achieved after 3 months. The recovery of
CD4 T-cell count following completion of chemotherapy was more rapid
than described for ARL patients who were not receiving concomitant
HAART. CONCLUSIONS: By combining chemotherapy with HAART, immune
function is better maintained in the medium term. The CD4 T-cell count
falls by 50% during chemotherapy and this will help to identify patients
who require opportunistic infection prophylaxis during chemotherapy.
6
UI - 11920242
AU - Boulanger E; Agbalika F; Maarek O; Daniel MT; Grollet L; Molina JM;
TI -
Sigaux F; Oksenhendler E
A clinical, molecular and cytogenetic study of 12 cases of human
herpesvirus 8 associated primary effusion lymphoma in HIV-infected
patients.
SO - Hematol J 2001;2(3):172-9
AD - Department of Clinical Immunohematology, Hopital Saint-Louis, Paris,
France.
INTRODUCTION: Primary effusion lymphoma is a rare type of B-cell
lymphoproliferative disorder which is mainly observed in patients with
HIV infection. Lymphomatous cells bridge features of immunoblastic and
anaplastic cells with a non-B non-T phenotype and are characterized by
the presence of the human herpesvirus 8 genome. We report on the
retrospective analysis of 12 cases. PATIENTS AND METHODS:: Twelve
HIV-infected patients with serous effusions containing large HHV8(+)
lymphomatous cells were extensively evaluated to disclose associated
visceral involvement. Clonality was assessed by IgH gene rearrangement
PCR analysis (n = 11) or Southern blot (n = 1). EBV and HHV8 DNA
sequences were detected by PCR analysis. Cytogenetics studies were
performed in seven cases using RHG-banding. RESULTS: Extraserous
localizations of lymphoma were present in six cases (50%): mediastinal
(n = 2), mesenteric (n = 2), pancreatic (n = 1), and bone marrow
involvement (n = 1). A monoclonal rearrangement of IgH genes was
demonstrated in six cases, an oligoclonal pattern in one, whereas no
clonality could be detected in five. High HHV8 copy numbers were
demonstrated in all effusion fluids, with EBV-co-infection in all cases
but one. Cytogenetic analysis displayed a complex karyotype in all cases
without recurrent abnormalities. Eight patients have died. Three
patients are in complete remission at 28, 53 and 55 months after
high-dose chemotherapy (n = 1), cidofovir and alpha-interferon
combination therapy (n = 1), and antiretroviral therapy alone (n = 1).
CONCLUSION: The clinical and molecular pattern, as well as the response
to therapy suggest that primary effusion lymphoma represents an
heterogenous type of virus-induced B-cell lymphoproliferative disorder,
sharing pathophysiological features with that induced by the
Epstein-Barr virus and occurring in immunocompromised patients.
7
UI - 11836577
AU - Silvestris N; Crucitta E; Lorusso V; Gamucci T; De Lena M
TI -
AIDS-related non-Hodgkin's lymphoma: clinico-pathological
characteristics and therapeutic strategies (review).
SO - Int J Oncol 2002 Mar;20(3):611-5
AD - Operative Unit of Medical Oncology, ASL of Frosinone, Bari, Italy.
High-grade B-cell non-Hodgkin's lymphoma (NHL), a diagnostic disease for
the acquired immunodeficiency syndrome (AIDS), is a late manifestation
of HIV infection and is generally related to severe lymphopenia. We
reviewed the main clinico-pathological features of this disease and
analysed its pathogenetic mechanisms with potential therapeutic
implications.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home